Plain Language Summaries is part of Taylor & Francis Group.

  • Taylor & Francis
  • About us
  • Our journals
  • Our Digital Hubs

Taylor & Francis Group is a trading division of Informa that operates through various Informa legal entities including, but not limited to, Informa UK Limited, with the registered address at 5 Howick Place, London, SW1P 1WG, UK.

Taylor & Francis
logo
 
  • How to
  • FAQs
  • Publications
  • Advisory Panel
    • Plain Language Advisors
    • Scientific Content Advisors
  • Supporters
  • Blog
  • About us
  • Contact Us

hematologic

22nd Jan 2026

Plain language summary: results of pre-transplant inotuzumab ozogamicin treatment in acute lymphoblastic leukemia patients

22nd Jan 2025

Plain language summary of the ASCEMBL study: comparing asciminib and bosutinib after multiple prior treatments for chronic myeloid leukemia

18th Oct 2024

Ruxolitinib treatment for polycythemia vera blood cancer: A plain language summary of the MAJIC-PV study

This plain language summary describes the results of a Phase 3 study called KarMMa-3. In this ongoing study, researchers looked at a relatively new treatment for people with multiple myeloma, a type of blood cancer, whose cancer got worse despite treatment (refractory) or had cancer that at first improved with treatment, but eventually stopped responding (relapsed)
30th Apr 2024

KarMMa-3 study: A plain language summary looking at the effectiveness of ide-cel for relapsed/refractory multiple myeloma

Copyright © 2026 · Plain Language Summaries · Terms and conditions · Privacy policy · Cookie policy